Bronchoconstriction (BC) is the main feature of anaphylaxis in the guinea pig. Since LPS induces lung inflammation and antigen-induced BC depends on the endogenous formation of histamine and arachidonate metabolites, we studied whether LPS might modulate antigen-induced BC. Guinea pigs were sensitized subcutaneously with 10 pg ovalbumin (OA) on days 0 and 14. LPS (100 gg/kg) was injected intravenously on day 21, and daily injections of LPS were continued before the antigenic challenge on day 22, 23, 24, or 25. Intratracheal injection of 100 pug OA induced an abrupt and reversible BC. Single or repetitive injections of LPS reduced BC. LPS is likely to reduce the OA-induced BC by affecting the histamine-dependent component of BC, since (a) LPS induced a partial degranulation of lung mast cells; (b) BC is reduced by mepyramine, an histamine receptor antagonist; (c) LPS did not affect BC in mepyraminetreated guinea pigs; (d) LPS reduced histamine release by OAstimulated guinea pig lungs in vitro. Moreover, the in vitro OA-induced production of arachidonate metabolites was also reduced by LPS. The decreased formation of TXB2 was not only secondary to a reduced release of histamine, since LPS inhibited TXB2 formation in the presence of mepyramine. Finally, the FMLP-induced BC and mediator release were inhibited by LPS, whereas the platelet activating factor-induced pulmonary responses were not. Thus, the protective effect of LPS is not antigen-specific and does not result from a general desensitization. These studies indicate that a single dose of LPS reduces the antigen-induced BC by reducing histamine release from lung mast cells, although a decreased formation of eicosanoids may contribute to the protective effect of LPS. (J. Clin.
Introduction
Lipopolysaccharide (endotoxin), the major outer cell wall component ofGram-negative bacteria, is a potent inducer ofinflam-matory reactions (1) (2) (3) . Paradoxically, LPS also displays antiinflammatory effects. Thus, a single dose of LPS markedly reduced lethality of mice during septicemia (4) and inhibited the vascular permeability changes and neutrophil exudation induced either in rabbit skin by reverse passive Arthus reaction (5) or in rat pleural cavity by carrageenan (6, 7) . Furthermore, LPS markedly, but transiently, reduced the local footpad swelling induced by injection of killed Mycobacteria butyricum in rabbits (8) . Similarly, Meier et al. (9) reported that a single dose ofbacterial polysaccharides derived from Proteus vulgaris protected against death from anaphylactic shock in guinea pigs. Finally, the same preparations inhibited (or suppressed) the active Arthus reaction in guinea pigs (9) .
Since the anaphylactic bronchoconstriction results from an immunologically induced inflammatory reaction, we now investigate if the lipopolysaccharide from Escherichia coli 055:B5 modulates the antigen-induced bronchoconstriction in actively sensitized guinea pigs. To characterize further the specificity and mechanism of the protective effect of LPS on anaphylactic bronchoconstriction, lungs isolated from sensitized guinea pigs were stimulated with the antigen, ovalbumin, or with nonantigenic related inflammatory stimuli, such as FMLP and platelet-activating factor (PAF). ' We now report that a single intravenous (i.v.) injection of LPS reduces the in vitro bronchoconstriction and mediator release induced by ovalbumin and FMLP, but does not modify the PAF-triggered pulmonary response.
Methods
Chemicals. The following reagents were purchased: FMLP, histamine, PGE2, 6-keto-PGFI., thromboxane (TXB2) (Sigma Chemical Co., St. Louis, MO); lysine acetylsalicylate (Synthelabo Laboratories, Paris, France); mepyramine maleate (Rhone-Poulenc Sant6, Vitry-sur-Seine, France); PAF (l-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine; Bachem, Bubendorf, Switzerland); pancuronium bromide (Organon, Fresnes, France); chicken ovalbumin (Miles Scientific Div., Naperville, IL). LY171883 was a gift from Dr. J.H. Fleisch (Eli Lilly Research Laboratories, Indianapolis, IN). LPS was purchased from Difco Laboratories Inc., Detroit, MI, and prepared by phenolic extraction (10) from Escherichia coli 055:B5. Sensitization procedure. 30 g of aluminum ammonium sulfate (Farmitalia Carlo Erba, Milano, Italy) suspended in 360 ml distilled water was mixed with 150 ml NaOH IN. This mixture was shaken at room temperature for 30 min until aluminum hydroxide precipitated. The precipitate was centrifuged at 1,500 g for 15 min and resuspended in distilled water. 500 AI of aluminum hydroxide gel (40 mg/ml) was mixed with 200 Al of ovalbumin solution (1 mg/ml) at room temperature for 1 h and then added to 9.3 ml of pyrogen-free saline. Male Hartley guinea pigs (300-350 g; Shamrock, Houdan, France) were in-jected subcutaneously (s.c.) with 0.5 ml of this solution on days 0 and 14. Pretreatment ofguinea pigs with LPS. Nonanesthetized guinea pigs were injected i.v. on day 21 with 100 Asg/kg of LPS. Daily injections of LPS were continued until the antigenic provocation with ovalbumin was given on one of the following days, day 22, 23, 24, or 25 . In all cases, the final injection of LPS was 24 h before the antigenic provocation. This pretreatment over 1, 2, 3, or 4 d is referred to as 24, 48, 72, or 96 h. Control guinea pigs were similarly injected with pyrogen-free saline.
In vivo anaphylactic shock. Guinea pigs were anesthetized with sodium pentobarbitone (40 mg/kg, intraperitoneal (i.p.); Clin-Midy, Montpellier, France). The trachea was cannulated and ventilation then started with a Palmer miniature respiratory pump (60 strokes/min). Both carotid arteries were cannulated to record the arterial blood pressure (P23Db transducer; Gould Inc., Oxnard, CA) and to collect blood samples for the platelet and leukocyte counts (Counter-ZBI; Coulter Electronics Inc., Hialeah, FL). Drugs were injected into the jugular vein. Guinea pigs were bilaterally vagotomized when drugs were administered through the airways. Spontaneous breathing was abolished with pancuronium bromide, a neuromuscular blocking agent (4 mg/ kg, i.v.) and bronchial resistance to inflation was recorded as previously described (1 1).
Three hours after the i.p. injection of sodium pentobarbitone, the bronchial reactivity was checked with serotonin (6 gsg, i.v.; Sigma).
Ovalbumin was either infused through the jugular vein at 0.75 mg/kg (in saline) for 10 min or injected intratracheally (i.t.) as a bolus of 100 Mug in 100 Mul saline. In the latter case, the airways resistance was not modified by the injection itself. To verify whether ovalbumin was evenly distributed in the airways, cross-sections of lungs from guinea pigs injected i.t. with Evans blue dye were performed 10 min later and were studded with numerous blue blobs throughout the parenchyma. Bronchoconstriction is defined as the increase in the bronchial resistance to inflation and is expressed as the area (in square centimeters) above baseline bronchial resistance (i.e., the increased pen displacement over the chart paper) over the 20-min period starting with either the infusion or the i.t. injection ofovalbumin. The number ofcirculating platelets and leukocytes was measured before and 1, 3, 5, 10, and 30 min after starting the infusion or after the i.t. injection.
Electron microscopy. Lung blocks (< 1 mm3) were fixed for 24 h in glutaraldehyde (2.5% in 100 mM PBS, pH 7.4). After washing in PBS, specimens were postfixed in 2% osmium tetroxide, dehydrated in graded alcohols, and then embedded in Epon 812-filled gelatin capsules. Ultrathin sections were prepared using an ultramicrotome (LKB Instruments, Inc., Gaithersburg, MD) and counterstained with uranyl acetate/lead citrate.
Perfusion of isolated guinea pig lungs. Guinea pigs were anesthetized as above. The trachea was cannulated and the animal was ventilated with a Palmer miniature respiratory pump (60 strokes/min). A thoracotomy was performed and lungs were washed through the cannulated pulmonary artery for 10 min with 50 ml Krebs solution (1 18.0 mM NaCl, 4.7 mM KCI, 2.5 mM CaCl2 -2H2O, 1.2 mM MgSO4 *7H20, 1.2 mM KH2PO4, 25.0 mM NaHCO3, 5.6 mM glucose), containing HSA (0.25%, wt/vol). Lungs were rapidly removed, ventilated with a Palmer miniature respiratory pump (40 strokes/min) through the cannulated trachea and immediately perfused (9 ml/min, 37°C) via the pulmonary artery with a gassed Krebs-HSA solution (95% 02-5% C02). Increase in bronchial resistance to inflation were continuously recorded with a Gould P23Db transducer. After a 10-min period of equilibration, increasing doses of ovalbumin (1 ng, 100 ng, and 10Mg) in 100 Ml saline were successively administered each 0-min period via the pulmonary artery. In a separate set of experiments, increasing doses of FMLP or PAF (1 and 100 ng) were first injected and followed by 10 ug of ovalbumin. Histamine, PGE2, TXB2, 6-keto-PGFia, LTB4, and LTC4 were evaluated in the lung effluent collected on ice over each 10-min period. Bronchoconstriction is expressed as the area (in square centimeters) above baseline bronchial resistance over a 1O-min period starting with each injection of stimulus as described above for the in vitro experiments. Mediator release was appreciated in every 3-min lung effluent fraction following each injection of stimulus.
Histamine assay. A l-ml aliquot of each lung effluent fraction was mixed with 1 ml ofperchloric acid 0.8 N and centrifuged at 40C for 20 min at 3,500 rpm. Supernatants were stored at 40C. Spectrofluorometric assays for histamine were performed according to Lebel ( 12) .
Radioimmunoassays of TXB2, 6-keto-PGFia, and PGE2. A 1-ml aliquot ofeach lung effluent fraction was immediately stored at -20'C for determination of PGE2. Another 1-ml aliquot was kept at room temperature for 60 min, allowing the conversion of TXA2 and PGI2 into their products oftransformation TXB2 and 6-keto-PGFI., respectively. Every I00-Ml sample ofeach lung effluent fraction was incubated overnight at 40C with one ofthe three 1251-labelled prostanoids and its respective antiserum (supplied by Prof. F. Dray, Institut Pasteur, Paris, France). Radiolabelled prostanoids (or their breakdown products) and antisera were dissolved in a phosphate buffer (100 mM, pH 7.4) containing bovine y-globulin fraction II (0.3%, wt/vol; Sigma). Bound and free fractions were separated by addition of polyethyleneglycol 6000 (30% in distilled water, Merck, Darmstadt, FRG) and centrifugation at 4°C for 10 min at 4,000 rpm. Radioactivity of the pellet (bound fraction) was counted for 1 min in a gamma counter. The monoclonal antibodies used were < 0.02% cross-reactive with PGD2, PGE2, PGF2, 6-keto-PGF,., and arachidonic acid for the anti-TXB2 antiserum; 10.9% cross-reactive with PGF2., and < 2.2% cross-reactive with PGD2, PGE2, and TXB2 for the anti-6-keto-PGFa antiserum; < 0.1 1% cross-reactive with PGD2, PGF2., and TXB2 for the anti-PGE2 antiserum. The sensitivities of anti-sera for TXB2, PGE2, and 6-keto-PGFIU were 12, 20, and 16 pg in a 100-Ml sample, respectively. Radioimmunoassays ofLTB and LTC4. A 1-mil aliquot of each lung effluent fraction was immediately stored at -20°C. Every 100-ul sample of each lung effluent fraction was incubated overnight at 4°C with either 3H-labelled LTB4 or 3H-labelled LTC4 (Amersham International, Amersham, UK), and its respective antiserum. Radiolabelled leukotrienes and antisera were dissolved in a phosphate buffer (100 mM, pH 7.4) containing gelatin type I (0.1%, wt/vol; Sigma). Bound and free fractions were separated by addition of dextran-coated charcoal (charcoal 0.5%, dextran 0.05% in phosphate buffer; Sigma) and centrifugation at 4°C for 10 min at 4,000 rpm. Supernatants were decanted into scintillation vials and were completed with aqueous counting scintillant ACS-II (5 ml; Amersham). Vials were counted for 1 min in a P scintillation counter. The monoclonal anti-LTB4 antibody (Amersham) was 0.4% cross-reactive with 20-OH-LTB4 and 6-trans-LTB4, and < 0.05% with LTC4, LTD4, TXB2, PGF2,,, 6-keto-PGFI., and arachidonic acid. The monoclonal anti-LTC4 antibody (gift from Dr. U. Zor, Weizmann Institute, Rehovot, Israel) was 10.0% crossreactive with LTD4 and < 0.1% with LTA4 and LTB4. Since the anti-LTC4 antiserum cross-reacts with LTD4, LTC4 was reported as immunoreactive LTC4 (iLTC4). The sensitivities of antisera for LTB4 and iLTC4 were 300 and 150 pg in a 100-Ml sample, respectively. Statistical analysis. Data were expressed as mean±SEM ofthe indicated number of experiments. Differences between LPS-and salinetreated groups were analyzed for significance by Student's two-tailed t test for unpaired samples. The level of significance was set to 5% (P < 0.05).
Results
Pulmonary, hematologic, and hemodynamic effects ofLPS in actively sensitized guinea pigs. A rapid and marked peripheral blood leukopenia was induced in sensitized guinea pigs by the i.v. injection of 100 pg/kg LPS (Table I) . Number ofleukocytes already fell to 50% (ofinitial values) at 10 min and plateaued at 15-25% from 30 to 120 min after LPS injection. This marked decrease in leukocyte counts was followed by a slight increase at 180 min. In these conditions, LPS failed to induce X variations in lung resistance to inflation (not si pressure, hematocrit values, or circulating plate] ble I).
Inhibition by LPS pretreatment of bronchoc duced by the infusion ofovalbumin. The infusior (0.75 mg/kg) over a 10-min period induced br( tion in sensitized guinea pigs ( Fig. 1 A) . Lunj inflation increased after a lag time of 3 min, pea min, and slowly recovered over the followin abrupt and marked arterial hypotension was re min and was followed within 3-5 min by a hype (not shown). Numbers of circulating leukocyte fell from 1 min on, and reached their nadir at 5 i Pretreatment of sensitized guinea pigs with prevented antigen-induced bronchoconstriction petitive i.v. injections of LPS (refered to as 48 significantly reduced ovalbumin-induced bro tion, whereas a single i.v. injection (24 h) was i] 2). Single or repetitive i.v. injections of LPS fai sO 10 min (Table II) (Table II) .
No further change in lung resistance to inflation was recorded when a second i.t. injection ofovalbumin was delivered 60 min later. In contrast, bronchoconstriction and hypotension were still triggered by an i.v. bolus ofovalbumin (1 mg/kg in 0.1 ml saline) injected 60 min after the first i.t. antigenic challenge (not shown).
Pretreatment of sensitized guinea pigs with 100 jig/kg LPS reduced bronchoconstriction induced by i.t. injection of ovalbumin ( Fig. 1 D) . A single i.v. injection (24 h) of LPS reduced bronchoconstriction more markedly than repetitive injections KAUUM (48, 72, or 96 h) did (Fig. 2 constriction was reduced to the same extent as mepyramine alone did ( Fig. 3) . Finally, the leukotriene D/E4 receptor antagonist LY1 71883 (30 mg/kg) did not significantly reduce (29%, P> 0.05) the ovalbumin-induced bronchoconstriction (Fig. 3) . Although histamine is the main mediator of the antigen-induced bronchoconstriction, ovalbumin still induces bronchoconstriction in propranololand mepyramine-injected guinea pigs (13) . To ( Fig. 4 B) . Their number was also reduced by LPS as shown by the open areas (arrows) indicating empty granules. Moreover, free secretory granules were observed in the extracellular matrix of the bronchial submucosa from LPS-treated guinea pig lungs (Fig. 4 C) .
Effect ofLPS on bronchoconstriction and mediator release by ovalbumin-stimulated guinea pig lungs. To provide additional evidence that a single i.v. injection of LPS affects a pulmonary target involved in the ovalbumin-induced bronchoconstriction, sensitized guinea pigs were injected i.v. on day 21 with either saline or LPS, and their lungs were exposed in vitro on day 22 to increasing doses of ovalbumin. In the salinetreated group, an intense but submaximal bronchoconstriction was already triggered by 1 ng ofovalbumin (Fig. 5, upperpanel) whereas a maximal response was evoked by the two following injections of ovalbumin (100 ng and 10 ag). In no case did the bronchial resistance to inflation recover its basal value in the 10-min period following each injection of ovalbumin. Pretreatment with 100 Mg/kg of LPS markedly reduced bronchoconstriction triggered by 1 ng (68% inhibition, P < 0.05) and 100 ng of ovalbumin (51% inhibition, P <0.05) but failed to reduce bronchoconstriction triggered by 10 Ag ofantigen (Fig. 5, upper panel).
In an attempt to explain the LPSinduced reduction in antigen-induced bronchoconstriction, we measured over time the levels of TXB2 and histamine in lung effluents. In the salinetreated group, release of TXB2 and histamine was already triggered by 1 ng of ovalbumin (Fig. 5 , middle and lower panels).
Histamine and TXB2 were essentially released within the first 3 mn, but significant amounts of TXB2 (as compared to basal values before stimulation) were still released within the next 3 min. Nevertheless, levels of histamine and TXB2 returned to their basal values within the last minute before the following injection of ovalbumin. No significant release ofboth mediator was induced by 100 ng of ovalbumin, indicating that lungs were then desensitized to ovalbumin by a previous injection of antigen (Fig. 5 , middle and lower panels). Finally, TXB2 and histamine were released by 10,ug of ovalbumin. However, it is noteworthy that a 10,000-fold increase in the dose of ovalbumin resulted only in an approximate two-to threefold increase in amounts of each mediator released (Fig. 5 , middle and lower panels). Pretreatment with 100 Mg/kg of LPS markedly inhibited the release of TXB2 (85% inhibition, P < 0.05) and histamine (85% inhibition, P < 0.01) induced by1 ng of ovalbumin (Fig. 5 , middle and lower panels) but had no effect on mediator release when100 ng of ovalbumin were injected. Finally, LPS pretreatment also reduced the release of TXB2 induced by10 ,ug of ovalbumin (8 1% inhibition, P< 0.00 1), but did not significantly modify the accompanying release of histamine. Among other eicosanoids measured in lung effluents of the saline-treated group, PGE2 showed the same pattern as described above for histamine and TXB2. Release of PGE2 was triggered by 1 ng of ovalbumin (not shown) and further evoked by 10 Mg of ovalbumin ( Fig. 6, upperpanel) . In contrast, detectable amounts of 6-keto-PGFa, LTB4, and iLTC4 were released only by 10 Mg of ovalbumin (Fig. 6, upper and lower panels) . Pretreatment with LPS reduced the release of PGE2 induced by 1 ng of ovalbumin (73% inhibition, P < 0.05) as well as the release of 6-keto-PGFia (73% inhibition, P < 0.01), PGE2 (62% inhibition, P < 0.05), LTB4 (68% inhibition, P < 0.01), and iLTC4 (68% inhibition, P < 0.05) induced by 10 Mg of ovalbumin (Fig. 6, upper and lower panels) . with either saline (1 ml/kg, n = 5) or LPS-(100 ,ug/kg, n = 5). Lungs were isolated 24 h later and processed as described in Methods. Relationship of arachidonate metabolite production and histamine release by lungsfrom LPS-treatedguinea pigs. Since histamine induces TXA2 production from perfused guinea pig lungs (14, 15) , the LPS-induced reduction in TXB2 production could result from a decreased capability to release histamine. Lungs from LPS-treated guinea pigs were stimulated with histamine, and TXB2 levels were measured in lung effluents within the first 3 min after histamine stimulation. LPS pretreatment significantly reduced (59% inhibition, P < 0.01) the release ofTXB2 triggered by 10 ng histamine (6.92±1.05 ng/ml [saline-treated group, n = 5] vs. 2.84+0.62 ng/ml [LPS-treated group, n = 5]).
To clarify further if the LPS-induced reduction in histamine release and arachidonate metabolite production are separate events, lungs from LPS-treated guinea pigs were stimulated with ovalbumin in the presence of mepyramine, a histamine H1 receptor antagonist. LPS pretreatment still reduced the release of TXB2 induced by 10 ,ug ofovalbumin (Table III) . Effect ofLPS on bronchoconstriction and mediator release by PAFor FMLP-stimulated guinea pig lungs. To determine whether a single i.v. injection ofLPS reduced bronchoconstriction and mediator release evoked by the only antigen or by non-antigen-related stimuli as well, lungs from sensitized guinea pigs were exposed to FMLP, a synthetic peptide mimicking the NH2 terminus of bacterial peptides, or to PAF, a lipid mediator released from the membrane of stimulated cells. Pretreatment with LPS failed to modify bronchoconstriction and release of TXB2 and histamine induced by 1 ng and 100 ng of PAF (Fig. 7) . In contrast, LPS pretreatment markedly inhibited bronchoconstriction induced by 1 ng (66% inhibition, P < 0.05) and 100 ng ofFMLP (46% inhibition, P < 0.05) (Fig. 8 , upper panel). Similarly, LPS pretreatment significantly reduced the release ofTXB2 and histamine induced by 1 ng (71% inhibition, P < 0.05) and 100 ng of FMLP (81% inhibition, P < 0.05) (Fig. 8 , middle and lower panels). Sensitized guinea pigs were injected i.v. with 100Og/kg LPS. Lungs were isolated 24 h later as described in Methods and were perfused with Krebs-HSA containing 3 X 10-6 M mepyramine. After a 0-min period equilibration, ovalbumin (OA, 10 ug in 100 ul saline) was administered via the pulmonary artery. * Levels of TXB2 (in nanograms per milliliter) were measured in lung effluent fractions collected before and within the next 6 min after the antigenic stimulation.
Lipopolysaccharide Reduces Antigen-induced Bronchoconstriction 1941 Figure 7 . Effect of LPS pretreatment on bronchoconstriction and release of thromboxane B2 and histamine by PAF-stimulated guinea pig lungs. Actively sensitized guinea pigs were injected i.v. with either LPS (100 ug/kg, n = 7, closed columns and squares) or saline (1 ml/kg, n = 5, open columns and squares). Lungs were isolated 24 h later and stimulated in vitro by increasing doses of PAF (1 ng and 100 ng), followed by 10 mg of ovalbumin. Differences in bronchoconstriction as well as release of thromboxane B2 and histamine between LPS-treated and saline-treated guinea pigs were statistically analyzed for significance (***P < 0.001) using Student's t test for unpaired samples.
Discussion
In these studies, we report that a low dose of LPS from Escherichia coli reduces antigen-induced bronchoconstriction in actively sensitized guinea pigs. Injected i.v. to the guinea pig, this single dose of LPS did not itself induce an endotoxinic shock, since neither a decrease in arterial blood pressure nor vasopermeation was recorded. Nevertheless, a severe leukopenia occurred as early as 30 min after LPS injection, which was reversible within the first 3 h. Moreover, LPS did not induce itselfany thrombocytopenia. In contrast to LPS, nonlethal doses of infused antigen induced bronchoconstriction, a reversible hypotension, thrombocytopenia, and leukopenia. Since the protective dose of LPS activated circulating leukocytes but did not induce hypotension or vasopermeation, it is unlikely that the LPS-mediated reduction in antigen-induced bronchoconstriction results from a refractory state due to a previous endotoxinic shock. (1 ml/kg, n = 4, open columns and squares). Lungs were isolated 24 h later and stimulated in vitro by increasing doses of FMLP (1 ng and 100 ng), followed by 10 1Ag of ovalbumin. Differences in bronchoconstriction as well as release of thromboxane B2 and histamine between LPS-treated and saline-treated guinea pigs were statistically analyzed for significance (*P < 0.05; **P < 0.01) using Student's t test for unpaired samples.
In the first set of experiments, when ovalbumin was injected i.v., the protective effect of LPS was only observed for repetitive and daily injections administered over a period of48 to 96 h before antigenic provocation. This lack ofprotection by a single dose ofLPS and the involvement ofsystemic mediators in the antigen-induced bronchoconstriction led us to speculate that modulation of a pulmonary response triggered by the i.v. route might result from a decreased release of mediators produced both systemically and locally. Therefore, to limit the participation of histamine released from circulating basophils and from other tissues such as the liver, ovalbumin was delivered i.t. Bronchoconstriction and hypotension developed earlier than after the i.v. infusion ofantigen and were not accompanied by significant modifications of the number of circulating platelets and leukocytes. In these conditions, anaphylactic bronchoconstriction was reduced by the LPS pretreatment earlier than when ovalbumin was administered i.v., suggesting that lungs from sensitized guinea pigs were already affected from the first day on by LPS pretreatment, irrespective of the route of ovalbumin administration.
Mepyramine markedly antagonized bronchoconstriction induced by i.v. (not shown) or i.t. ovalbumin, under conditions where neither the LTD4/LTE4 receptor antagonist LY171883 (16), nor the cyclooxygenase inhibitor aspirin, or PAF antagonists (17) is effective. Histamine is thus the main mediator of the in vivo bronchopulmonary response to antigen, in agreement with previous studies (18, 19) . Histamine was also released by ovalbumin-stimulated lungs isolated from actively sensitized guinea pigs. Since in vivo anaphylactic bronchoconstriction and in vitro histamine release were both inhibited by LPS, a reduced capability oflungs from LPS-treated animals to release histamine in vivo and ex vivo in response to antigen might account for the protective effect of LPS on bronchoconstriction. Furthermore, antigen-induced bronchoconstriction in propranololand mepyramine-injected guinea pigs was not reduced by LPS pretreatment, supporting the hypothesis that the histamine-dependent component ofthe anaphylactic bronchoconstriction is the main target responsible for the protective effect of LPS. Electron microscopic studies indicated that a single dose ofLPS induces a partial degranulation ofthe pulmonary mast cells. Nevertheless, this LPS-induced release ofhistamine should be protracted and subeffective, since i.v. injections ofLPS did not trigger any increase in bronchial resistance to inflation. Thus, a reduced capability of lungs from LPStreated animals to release histamine due to a partial mast cell degranulation may account for the protective effect of LPS on antigen-induced bronchoconstriction.
Because it is unlikely that a single mediator, histamine, could explain all of the changes occurring in anaphylaxis, we have investigated the effect of LPS pretreatment on eicosanoid release from lungs of sensitized guinea pigs. A single dose of LPS reduced the in vitro antigen-induced production of the arachidonate metabolites TXA2, PGE2, PGI2, LTB4, and iLTC4. Significant reduction in release of prostaglandins and leukotrienes by isolated lungs perfused free of circulating cells suggests that resident lung cells or previously elicited cells are the likely target accounting for the LPS-induced decrease in eicosanoid production. Therefore, mast cells (20, 21) , alveolar macrophages, eosinophils (22) , and endothelial cells (23) are both the likely source of eicosanoids and a possible target of LPS pretreatment. A decreased release ofTXA2 and LTC4 may contribute to the protective effect ofLPS since both TXA2 and LTC4 are potent bronchoconstrictors of the guinea pig lung (24, 25) . LPS pretreatment also reduced the antigen-induced release of LTB4, a less potent bronchoconstrictor ofguinea pig lung than LTC4 (25) . Release ofthe bronchorelaxant PGE2 was reduced by LPS pretreatment, ruling out a direct regulatory effect of PGE2 on smooth muscle contraction (26) as a possible explanation for the protective effect ofLPS. Finally, the production of PGI2 was also reduced by LPS pretreatment, indicating that endothelial cells of the pulmonary vasculature were affected by LPS. The decrease in production ofeicosanoids after a long-term exposure to LPS is in sharp contrast with the shortterm priming effect of LPS on eicosanoid synthesis by inflammatory cells (27, 28) or perfused lungs (29) .
Since histamine induces TXA2 formation from perfused guinea pig lungs (14, 15) , the release of histamine may be the rate-limiting step for a subsequent formation of arachidonate metabolites. In our studies, LPS pretreatment suppressed the release of TXB2 triggered either by histamine itself or ovalbumin in the presence of mepyramine, a histamine H. receptor antagonist. Moreover, LPS pretreatment suppressed the formation of TXA2, PGE2, PGI2, LTB4, and iLTC4, but failed to reduce release ofhistamine induced by 10 Aig ovalbumin. These results suggest that inhibition of histamine release and TXB2 formation by LPS are separate events, even though the LPS-induced decrease in histamine release may contribute to the reduction in arachidonate metabolite production. Furthermore, a decreased production ofboth cyclooxygenase and lipoxygenase products suggests that a proximal step in the cyclooxygenase and lipoxygenase pathways, such as availability of arachidonic acid, may be the limiting step affected by LPS pretreatment. Although LPS has been reported to increase phospholipase A2 (PLA2) activity in rat lungs (30) and rabbit peritoneum (31), a decreased PLA2 activity is thought to be a subcellular mechanism accounting for an increase in airways hyperreactivity of guinea pig trachea 4 d after LPS injection (32) . Therefore, it is possible that an early LPS-induced increase in PLA2 activity is followed by a decrease ofa stimuli-induced PLA2 activity, explaining the reduced capability of pulmonary cells to generate prostaglandins and leukotrienes after LPS pretreatment.
The LPS-induced protection was not antigen-specific, since the FMLP-induced bronchoconstriction and release of histamine and TXB2 were also reduced. Previous studies have shown that FMLP-induced chemotactic response and superoxide generation of rabbit PMNs are not affected by in vivo LPS pretreatment (33) , although LPS induced an increase in FMLP receptor density (34). Such an uncoupling of receptors for FMLP might also explain the protective effect of LPS on the FMLP-induced pulmonary responses, in our model. The protective effect ofLPS is unlikely to result from a general desensitization since PAF-induced bronchoconstriction and release of histamine and TXB2 were not inhibited by LPS pretreatment. From these results, it could also be stressed that different pathways lead to activation of lung cells by PAF, FMLP, and ovalbumin. Moreover, the lack of protective effect of LPS on the PAF-induced histamine release reinforces the concept ofa partial degranulation of pulmonary mast cells upon injection of LPS.
Our findings indicate that a single dose of LPS reduces the antigen-induced bronchoconstriction in actively sensitized guinea pigs. The histamine-dependent component appears to be the main target accounting for the protective effect of LPS. Moreover, the LPS-induced decrease in histamine release and eicosanoid production are separate events, suggesting that LPS might also be protective in inflammatory reactions where eicosanoids play a major role. Our surprising results lead us to conclude that the protective effect of LPS may counteract its well-known priming effect on inflammatory reactions. Such dual effect of LPS may modulate pulmonary allergic reactions, frequently associated with inflammation, or even bacterial infections. LPS is a potent inducer of IL-1, and a single low dose of IL-1 has been reported to inhibit inflammation in rabbit colitis (35) , antigen-induced arthritis in rats (36) , and contact hypersensitivity responses in mice (37) . Further investigations will indicate whether IL-1, or other cytokines with histaminereleasing activities, mediates the protective effect of LPS on antigen-induced pulmonary responses.
